Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Veracyte Inc is a biotechnology business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 320 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $30.34 |
|---|---|
| 52-week range | $31.41 - $86.03 |
| 50-day moving average | $43.20 |
| 200-day moving average | $43.48 |
| Wall St. target price | $64.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.13 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $30.34 from 2022-01-14
| 1 week (2022-01-06) | -13.61% |
|---|---|
| 1 month (2021-12-17) | -32.56% |
| 3 months (2021-10-13) | -30.81% |
| 6 months (2021-07-17) | -22.99% |
| 1 year (2021-01-15) | -40.26% |
|---|---|
| 2 years (2020-01-17) | 0.63% |
| 3 years (2019-01-17) | 85.57% |
| 5 years (2017-01-17) | 293.51% |
| Revenue TTM | $186.7 million |
|---|---|
| Gross profit TTM | $62.6 million |
| Return on assets TTM | -2.38% |
| Return on equity TTM | -9.55% |
| Profit margin | -39.14% |
| Book value | $15.59 |
| Market capitalisation | $2.4 billion |
TTM: trailing 12 months
We're not expecting Veracyte to pay a dividend over the next 12 months.
Over the last 12 months, Veracyte's shares have ranged in value from as little as $31.41 up to $86.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 0.7973. This would suggest that Veracyte's shares are less volatile than average (for this exchange).
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc. ; and Bayer AG.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
